About
1 Research Background
Heart failure with reduced ejection fraction (HFrEF) is a high-incidence, high-mortality cardiovascular disease with complex pathological mechanisms. Current clinical interventions still have limitations in individualized treatment and long-term prognosis improvement. Traditional Chinese medicine compound formulas exhibit multi-component, multi-target, and multi-pathway therapeutic characteristics, which are suitable for the systematic regulation of complex cardiovascular diseases.
2 Research Significance
This study takes Zhenwu Huangqi Decoction as the research object, and systematically reveals its potential material basis and molecular mechanism against HFrEF through network pharmacology and multi-omics bioinformatics strategies. It provides theoretical reference for subsequent experimental verification, clinical application and new drug development.
3 Introduction of Zhenwu Huangqi Decoction
Zhenwu Huangqi Decoction (ZWHQD) is modified based on classical Zhenwu Decoction, composed of six medicinal herbs: - Aconiti Radix Lateralis Preparata - Poria Cocos - Atractylodis Macrocephalae Rhizoma - Paeoniae Radix Alba - Zingiberis Rhizoma Recens - Astragali Radix
The formula warms yang, promotes diuresis, tonifies qi and activates blood, and has long been used in the clinical adjuvant treatment of chronic heart failure.
4 General Research Idea
- Screen bioactive ingredients of ZWHQD and predict corresponding drug targets.
- Mine differential genes and co-expression modules of HFrEF based on GEO transcriptome datasets.
- Construct compound-target-disease PPI network and screen hub genes.
- Perform functional enrichment, immune infiltration and single-cell expression profiling analysis.
- Use Mendelian randomization and colocalization to infer causal genes related to HFrEF.
- Construct diagnostic prediction model and verify core mechanism via single-gene GSEA and molecular docking.
| Home | Methods | Results | Start Analysis |